Best of the Blog: IN VIVO February 2009
Executive Summary
A roundup of our best February blog posts not covered elsewhere in the magazine includes Biotech's Winter and the March of the EarnOuts; Infant formula division Mead Johnson milks investors of $720 million in IPO; Dont Come Knockin' on my Door: Survey shows physicians restrict drug rep access.
You may also be interested in...
Lundbeck Looks To Replace Lexapro Earnings Through Ovation Purchase
Acquisition will enhance Lundbeck’s CNS pipeline and add a needed U.S. specialty sales force.
Endo Branches Out With $370M Indevus Acquisition
Re-submission of Nebido NDA in the wings, sales force will target general practitioners with urology, endocrinology drugs to general practitioners.
Ending the Arms Race: Ten Priorities for Fixing the Commercial Model
Faced with growing budgets and declining effectiveness of commercial spending, most large companies have embarked on the next wave of significant commercial changes. But most of these efforts don't go far enough to address the rapid and fundamental changes in the stakeholder landscape which have knocked pharma dramatically out of alignment with its stakeholder base. The article describes ten priorities for drug companies to align their organizations with these new realities - including requirements for companies to partner with payors and providers in new ways, and make resource decisions much more selectively to focus on the stakeholders who really matter. Nonetheless, these changes won't have their full effect without a more fundamental rethinking of the industry's value proposition, taking into account not only product value, but the services and the customer experience offered to all stakeholders.